Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers
05:45pm, Wednesday, 21'st Jul 2021
Novartis (NVS) reports mixed results for the second quarter, as key brands maintain momentum and businesses show signs of recovery.
Novartis CEO: Demand has surged for therapeutics
04:20pm, Wednesday, 21'st Jul 2021
Novartis CEO Vas Narasimhan joins "Closing Bell" to discuss the company's quarter and demand for theapeutics. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NG
15 European Dividend Aristocrats to Diversify Your Portfolio
01:47pm, Wednesday, 21'st Jul 2021
Plenty of investors focus in on dividends, and dividend aristocrats, but if those investors only look in the U.S. they could be missing out. The post 15 European Dividend Aristocrats to Diversify Your
Novartis AG (NVS) CEO Vas Narasimhan on Q2 2021 Results - Earnings Call Transcript
12:18pm, Wednesday, 21'st Jul 2021
Novartis AG (NVS) CEO Vas Narasimhan on Q2 2021 Results - Earnings Call Transcript
Novartis Posts Q2 Earnings Beat As Sales Pick Up; Reiterates 2021 Guidance
05:07am, Wednesday, 21'st Jul 2021
Novartis AG (NYSE: NVS) boosted its second-quarter core net income by 20% Y/Y to $3.7 billion, beating market expectations as it kept its 2021 guidance. Earnings: The Company posted core EPS of $1
Novartis posts Q2 profit beat, keeps 2021 guidance
01:28am, Wednesday, 21'st Jul 2021
ZURICH (Reuters) -Novartis boosted its second-quarter core net income by a fifth, beating market expectations, the Swiss drugmaker reported on Wednesday, as it kept its 2021 guidance.
Why Novartis (NVS) Might Surprise This Earnings Season
10:53am, Tuesday, 20'th Jul 2021
Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Basel, July 20, 2021 — Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Moreho
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
02:04pm, Sunday, 11'th Jul 2021
Several drugmakers have important clinical trial updates on the way.
Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant
09:04am, Thursday, 08'th Jul 2021
Molecular Partners AG (NASDAQ: MOLN) reported on the clinical progress of its antiviral candidate, ensovibep, as part of a presentation with its partner Novartis AG (NYSE: NVS) at the Credit Suiss
102 'Top Dividend Stocks On Earth' July Update
07:04am, Sunday, 04'th Jul 2021
Kiplinger "insights for investors" online, first listed 91 "Top Dividend Stocks From Around The World" 7/13/20. Two recent Kiplinger articles provided 102 Top Dividend Stocks on Earth as of 7/1/21. 39
Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on
09:01am, Friday, 02'nd Jul 2021
Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.
Novartis Looks To Enter mRNA Technology, Says Chairman: Reuters
03:08pm, Thursday, 01'st Jul 2021
Novartis AG (NYSE: NVS) could get into the field of messenger ribonucleic acid (mRNA) technology, reported Reuters, citing Chairman Joerg Reinhardt in a newspaper interview. In the Aargauer Zeitung
Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact
03:17pm, Tuesday, 29'th Jun 2021
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it accidentally overpaid by nearly $210 m
Novartis fights Roche in $210 million U.S. dispute over licensing fees
09:57am, Tuesday, 29'th Jun 2021
Novartis wants Roche to return $210 million after accusing its Swiss rival of inappropriately pocketing fees from a 16-year-old patent licensing agreement, according to a U.S. District Court lawsuit.
